Save information for later
Sign Up

Learn About Dystrophic Epidermolysis Bullosa

What is the definition of Dystrophic Epidermolysis Bullosa?

Dystrophic epidermolysis bullosa is one of the major forms of a group of conditions called epidermolysis bullosa. Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems.

What are the causes of Dystrophic Epidermolysis Bullosa?

Mutations in the COL7A1 gene cause all forms of dystrophic epidermolysis bullosa. This gene provides instructions for making a protein that forms the pieces (subunits) of a larger protein called type VII collagen. Collagens are proteins that give structure and strength to connective tissues, such as skin, tendons, and ligaments, throughout the body. Type VII collagen plays an important role in strengthening and stabilizing the skin. It is the main component of structures called anchoring fibrils, which anchor the top layer of skin, called the epidermis, to an underlying layer called the dermis.

How prevalent is Dystrophic Epidermolysis Bullosa?

Considered together, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated to be 3.3 per million people.

Is Dystrophic Epidermolysis Bullosa an inherited disorder?

Recessive dystrophic epidermolysis bullosa (RDEB-sev gen and RDEB-gen and -loc) is inherited in an autosomal recessive pattern. Autosomal recessive inheritance means that both copies of the COL7A1 gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

Who are the top Dystrophic Epidermolysis Bullosa Local Doctors?
Elite in Dystrophic Epidermolysis Bullosa
Elite in Dystrophic Epidermolysis Bullosa
13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
Languages Spoken:
English
Accepting New Patients

Anna Bruckner is a Dermatologist in Aurora, Colorado. Dr. Bruckner is rated as an Elite provider by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex. Dr. Bruckner is currently accepting new patients.

Elite in Dystrophic Epidermolysis Bullosa
Elite in Dystrophic Epidermolysis Bullosa
School Of Life Course Sciences, 
London, ENG, GB 

John Mcgrath practices in London, United Kingdom. Mr. Mcgrath is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. His top areas of expertise are Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Kindler Syndrome, Cystectomy, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dystrophic Epidermolysis Bullosa
Elite in Dystrophic Epidermolysis Bullosa
Paris, FR 

Alain Hovnanian practices in Paris, France. Mr. Hovnanian is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. His top areas of expertise are Netherton Syndrome, Dystrophic Epidermolysis Bullosa, Olmsted Syndrome, and Epidermolysis Bullosa.

What are the latest Dystrophic Epidermolysis Bullosa Clinical Trials?
A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez

Summary: In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JE...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Summary: The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Who are the sources who wrote this article ?

Published Date: February 01, 2020
Published By: National Institutes of Health